Literature DB >> 20736228

Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr mice.

Krisztián Papp1, Péter Végh, Andrey Tchorbanov, Tchavdar Vassilev, Anna Erdei, József Prechl.   

Abstract

OBJECTIVES: Nucleic acids are known to induce complement activation, which results in the masking and removal of apoptotic cells exposing nuclear components. Dysregulation of these events is characteristic of SLE, a systemic autoimmune disease characterized by the appearance of ANAs. In this study, we aimed to investigate the relationship between development of ANAs and their effect on complement activation by nucleic acids.
METHODS: We used protein array technology to characterize complement activation by murine mAbs and polyclonal antibodies against various forms of nucleic acid. Serum samples from MRL/lpr mice were collected, starting before the onset of the disease till 6 months of age. Binding of IgG and its subclasses to dsDNA, ssDNA, RNA, plasmid DNA and nucleosome complexes was determined, along with C3 fixation.
RESULTS: We show that complement C3 binding to various forms of nucleic acid that serve as targets in lupus is absent in normal serum. The addition of dsDNA-specific mAbs to normal serum results in the deposition of complement C3 to nucleic acids. In MRL/lpr mice, IgG antibodies against various nuclear antigens appear with ageing and disease progression. C3 binding to the antigens is somewhat delayed and suggests that accumulation or maturation of pathogenic antibodies is required for inducing C3 binding to ICs containing nucleic acids.
CONCLUSIONS: C3 deposition on nuclear antigens, therefore, reflects the state of disease progression in this murine model of SLE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736228     DOI: 10.1093/rheumatology/keq278

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

Review 1.  Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.

Authors:  Imre Kacskovics; Judit Cervenak; Anna Erdei; Richard A Goldsby; John E Butler
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

Review 2.  Complement in Lupus Nephritis: New Perspectives.

Authors:  Lihua Bao; Patrick N Cunningham; Richard J Quigg
Journal:  Kidney Dis (Basel)       Date:  2015-06-30

3.  Suppression of autoreactive T and B lymphocytes by anti-annexin A1 antibody in a humanized NSG murine model of systemic lupus erythematosus.

Authors:  N Mihaylova; P Chipinski; S Bradyanova; T Velikova; E Ivanova-Todorova; S Chausheva; M Herbáth; D Kalinova; J Prechl; D Kyurkchiev; A I Tchorbanov
Journal:  Clin Exp Immunol       Date:  2019-12-04       Impact factor: 4.330

Review 4.  Why current quantitative serology is not quantitative and how systems immunology could provide solutions.

Authors:  József Prechl
Journal:  Biol Futur       Date:  2021-02-20

5.  Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice.

Authors:  Jiwon Yang; Hye-Na Ahn; Minsun Chang; Purnima Narasimhan; Pak H Chan; Yun Seon Song
Journal:  J Neurochem       Date:  2012-12-28       Impact factor: 5.372

6.  Increased level of B cell differentiation factor in systemic lupus erythematosus patients.

Authors:  Hala Zaki Raslan; Hiba Sibaii; Salwa Refat El-Zayat; Hagar Hassan; Mahitab El-Kassaby
Journal:  J Genet Eng Biotechnol       Date:  2018-05-30

7.  Immune complex signatures of patients with active and inactive SLE revealed by multiplex protein binding analysis on antigen microarrays.

Authors:  Krisztián Papp; Péter Végh; Renáta Hóbor; Zoltán Szittner; Zoltán Vokó; János Podani; László Czirják; József Prechl
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.